Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes

Gene Therapy

Volumn 4, Issue 8, 1997, Pages 861-867

  Ramezani, A ^a   Ding, S F ^a   Joshi, S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gene therapy; Hammerhead ribozymes; HIV 1; Retroviral vector

Indexed keywords

CD4 ANTIGEN; RIBOZYME; VIRUS DNA; VIRUS VECTOR;

ARTICLE; CELL LINE; GENETIC TRANSDUCTION; HUMAN IMMUNODEFICIENCY VIRUS 1; NORTHERN BLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS REPLICATION;

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030775529     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300474     Document Type: Article

References (43)

1. Pomerantz RJ, Trono D. Genetic therapies for HIV infections: promise for the future AIDS 1995; 9: 985-993.
2. Rossi JJ, Elkin D, Zaia JA, Sullivan S. Ribozymes as anti-HIV-1 therapeutic agents, principles, applications and problems AIDS Res Hum Retrovir 1992; 8: 183-189.
3. Smythe JA, Symonds G. Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection. Inflamm Res 1995; 44: 11-15.
4. Dropulic B, Lin HN, Martin MA, Jeang KT. Functional characterization of a U5 ribozyme: intracellular suppression of HIV-1 expression. J Virol 1992; 66: 1432-1441.
5. - lymphocyte-derived cell lines using retroviral vectors expressing an HIV-1 RNA specific ribozyme. J Virol 1991; 65: 5531-5534.
6. Ventura M, Wang P, Franck N, Saragosti S. Ribozyme targeting of HIV-1 LTR. Biochem Biophys Res Commun 1994; 203: 889-898.
7. Dropulic B, Jeang KT. Intracellular susceptibility to ribozymes in a tethered substrate-ribozyme provirus model is not predicted by secondary structures of HIV-1 RNAs in vitro. Antisense Res Devel 1994; 4: 217-221.
8. Sun L-Q et al. Ribozyme-mediated suppression of MoMuLV and HIV-1 replication in permissive cell lines Proc Natl Acad Sci USA 1994; 91: 9715-9719.
9. Ramezani A, Joshi S. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo. Antisense Nucl Acid Drug Dev 1996; 6: 229-235.
10. Sarver N et al. Ribozymes as potential HIV-1 therapeutic agents. Science 1990; 247: 1222-1225.
11. Chen CJ et al. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 Env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 1992; 20: 4581-4589.
12. Crissell P, Thompson S, James W. Inhibition of HIV replication by ribozymes that show poor activity in vitro. Nucleic Acids Res 1993; 21: 5251-5255.
13. Sun LQ et al. Resistance to HIV-1 infection conferred by transduction of PBLs with ribozymes, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci USA 1995; 92: 7272-7276.
14. Zhou C et al. Inhibition of HIV-1 in human T lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994; 149: 33-39.
15. Lo KM et al. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 1992; 190: 176-183.
16. Sun LQ, Wang L, Gerlach WL, Symonds G. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res 1995; 23: 2909-2913.
17. Larsson S et al. A novel ribozyme target site located in the HIV-1 nef open reading frame. Virology 1996; 219: 161-169.
18. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F. Inhibition of HIV-1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 1992; 89: 10802-10806.
19. Yu M et al. A hairpin ribozyme inhibits expression of diverse strains of HIV-1. Proc Natl Acad Sci USA 1993; 90: 6340-6344.
20. Yamada O et al. Intracellular immunization of human T cells with a hairpin ribozyme against HIV-1. Gene Therapy 1994; 1: 38-45.
21. Yamada O et al. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Virology 1994; 205: 121-126.
22. Yu M et al. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology 1995; 206: 381-386.
23. Leavitt MC et al. Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther 1994; 5: 1115-1120.
24. Yu M et al. Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against HIV-1. Proc Natl Acad Sci USA 1995; 92: 699-703.
25. Ohkawa J, Yuyama N, Taira K. Activities of HIV RNA targeted ribozymes transcribed from a 'shot-gun' type ribozymetrimming plasmid. Nucleic Acids Symp Series 1992; 27: 15-16.
26. Ohkawa J et al. Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against HIV. Proc Natl Acad Sci USA 1993; 90: 11302-11306.
27. Joshi S, Davison L, Van Brunschot A, Van der Elst I. A retroviral vector to allow constitutive and Tat-inducible gene expression for anti-HIV-1 gene therapy. Mol Biol Life Sci Adv 1993; 12: 135-189
28. Heleseth E et al. Rapid complementation assays measuring replicative potential of HIV-1 envelope glycoprotein mutants. J Virol 1990; 64: 2415-2420.
29. Lori F et al. Viral DNA carried by HIV-1 virions. J Virol 1992; 66: 5067-5074.
30. Arts EJ, Mak J, Kleiman L, Wainberg MA. Mature RT (p66/p51) is responsible for low level of viral DNA found in HIV-1. Leukemia 1994; 8 (Suppl. 1): S175-S178.
31. Goff SP. Retroviral RT: syntheses, structure and function. J AIDS 1990; 3: 817-831.
32. Arts EJ, Wainberg MA. HIV-1 reverse transcriptase and early events in reverse transcription. Adv Virus Res 1996; 46: 97-163.
33. Melekhovets YF, Joshi S. Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro. Nucleic Acids Res 1996; 24: 1908-1912.
34. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33: 153-159.
35. Joshi S, Van Brunschot A, Robson I, Bernstein A. Efficient replication, integration and packaging of retroviral vectors modified LTR containing the packaging signal. Nucleic Acids Res 1990; 18: 4223-4226.
36. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
37. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to AZT isolated during prolonged therapy. Science 1989; 243: 1731-1734.
38. Pauwels R et al. Sensitive and rapid assay on MT4 cells for detection of antiviral compounds against the AIDS virus. J Virol Meth 1987; 16: 171-185.
39. + lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s). Antisense Res Dev 1994; 4: 19-26.
40. Liem SE, Ramezani A, Li X, Joshi S. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum Gene Ther 1993; 4: 625-634.
41. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
42. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press, New York, 1989.
43. Adachi A et al. Production of AIDS associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J Virol 1986; 59: 284-291.